Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multicenter phase III trial in patients with advanced gynecologic malignancies

Michael A. Gold, Joan L. Walker, Jonathan S. Berek, Alton V. Hallum, Dava J. Garcia, David S. Alberts

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Objective. To determine if amifostine could reduce the hematologic toxicity associated with topotecan. Methods. Thirty patients with recurrent/refractory gynecologic malignancies were randomized to receive topotecan (TOPO) (1.5 mg/m2/day days 1-5) with or without amifostine (AMI/TOPO) (500 mg/m2/day days 1-5) every 3 weeks for six cycles. The primary study endpoints were the incidence of grade 3 and 4 neutropenia. Results. Fifteen patients were randomized to each arm for a total of 49 TOPO and 53 AMI/TOPO cycles. Patient characteristics and pretreatment ANC were similar between groups. Topotecan 1.5 mg/m2/day days 1-5 was initially administered to seven patients. Five developed neutropenic fevers, one an uncomplicated grade 4 neutropenia, and the other an uncomplicated grade 3 neutropenia. There were two treatment-related deaths due to sepsis (one in each treatment arm). The starting dose was thereafter reduced to 1.25 mg/m2/day days 1-5 every 21 days. No treatment related deaths occurred after this dose reduction. The incidence of combined grade 3/4 neutropenia was reduced from 67% (33/49 cycles) to 38% (20/53 cycles) with the addition of amifostine (P = 0.003; OR 0.29; 95% CI 0.12-0.71). Conclusions. Topotecan at 1.5 mg/m2/day days 1-5 in heavily pretreated patients resulted in excessive toxicity not manageable with amifostine. At the reduced topotecan dose (1.25 mg/m2 × 5 days), pretreatment with amifostine reduced the hematologic toxicity associated with topotecan chemotherapy in women with recurrent/refractory gynecologic malignancies.

Original languageEnglish (US)
Pages (from-to)325-330
Number of pages6
JournalGynecologic oncology
Volume90
Issue number2
DOIs
StatePublished - Aug 1 2003

Keywords

  • Amifostine
  • Hematologic toxicity
  • Neutropenia
  • Thrombocytopenia
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multicenter phase III trial in patients with advanced gynecologic malignancies'. Together they form a unique fingerprint.

  • Cite this